Endocrine consequences of anorexia nervosa

Lancet Diabetes Endocrinol. 2014 Jul;2(7):581-92. doi: 10.1016/S2213-8587(13)70180-3. Epub 2014 Apr 2.

Abstract

Anorexia nervosa is prevalent in adolescents and young adults, and endocrine changes include hypothalamic amenorrhoea; a nutritionally acquired growth-hormone resistance leading to low concentrations of insulin-like growth factor-1 (IGF-1); relative hypercortisolaemia; decreases in leptin, insulin, amylin, and incretins; and increases in ghrelin, peptide YY, and adiponectin. These changes in turn have harmful effects on bone and might affect neurocognition, anxiety, depression, and the psychopathology of anorexia nervosa. Low bone-mineral density (BMD) is particularly concerning, because it is associated with changes in bone microarchitecture, strength, and clinical fractures. Recovery leads to improvements in many--but not all--hormonal changes, and deficits in bone accrual can persist. Oestrogen-replacement therapy, primarily via the transdermal route, increases BMD in adolescents, although catch-up is incomplete. In adults, oral oestrogen--combined with recombinant human IGF-1 in one study and bisphosphonates in another--increased BMD, but not to the normal range. More studies are necessary to investigate the optimum therapeutic approach in patients with, or recovering from, anorexia nervosa.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Anorexia Nervosa / complications*
  • Anorexia Nervosa / metabolism*
  • Bone Density
  • Human Growth Hormone / metabolism
  • Humans
  • Hydrocortisone / metabolism
  • Hypothalamo-Hypophyseal System / metabolism*
  • Insulin-Like Growth Factor I / metabolism
  • Pituitary-Adrenal System / metabolism*
  • Young Adult

Substances

  • Human Growth Hormone
  • Insulin-Like Growth Factor I
  • Hydrocortisone